Panacea Biotec

Innovation in support of life

Press Release
For Immediate Release

Panacea Biotec vows to protect millions of infants across the world from five infectious diseases

Alliance with GAVI to reduce cost of its Pentavalent Vaccine – EasyFive

New Delhi' June 05, 2011: Panacea Biotec, India's biggest vaccine manufacturer who introduced world's first fully liquid Pentavalent vaccine EasyFive in Jan., 2005 has pledged to support the cause of GAVI alliance by further reducing the cost of its Pentavalent Vaccine – EasyFive, to the tune of 10-15% in coming years, thereby increasing access of vaccines to more millions of children. After introduction of EasyFive in developing countries in year 2008 price of Pentavalent vaccine was brought down by 18% in 2010. The new vaccine price reductions will help to some extent on donor support for GAVI & contribute to reducing GAVI's funding challenge.

Announcing the commitment, Dr. Rajesh Jain, Jt. Managing Director, Panacea Biotec Ltd said – "We are very happy to extend our continued, unequivocal & unstinted support to GAVI for this noble social cause as developing countries are facing severe challenges in saving children's lives and protecting people's health.

The combined demand of all combination pediatric vaccines worldwide is estimated to grow up to USD 1.6 billion by 2012. Pentavalent vaccine market is estimated to cross a mark of USD 1 billion out of which UN agencies are likely to procure vaccines worth more than USD 425 million in 2011.

"Making vaccines affordable as demands grow is the only model which can create sustainable interest with Governments, Donors and other International Agencies to ensure each child is immunized from protectable disease", **said Dr. Rajesh Jain.**

Panacea Biotec has a long term agreement with UNICEF to supply 75 million doses for the year 2010, 2011 and 2012.

Panacea Biotec Ltd.

Panacea Biotec

Innovation in support of life

About Panacea Biotec and EasyFive

EasyFive is world's first fully liquid pentavalent vaccine developed by Panacea Biotec and introduced in India in January 2005, which immunizes children against five dreadful diseases (Diptheria+ Tetanus+ whole cell Pertussis+ Hepatitis B+ Hemophilus Influenza Type b) of early childhood,

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- 2010) and is also amongst the top 50 companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers. The company has around 3800 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

For further details please contact:



1. R.K.Suri
Chief Executive- Biologicals
Panacea Biotec Ltd
B-1,Extn./ A-27, Mohan Co-op.
Indl.Estate, Mathura Road
New Delhi-110044
INDIA
Phone: +91 11 41679000 Extn 2064; Fax: +91 11 41679027
Mobile: +91 9810194483 /+91 9971015411
e mail: rksuri@panaceabiotec.com
web: www.panaceabiotec.com

2. Subhash Y Mantri
G.M. - Corporate Communication
Panacea Biotec Ltd.
B-1 Extn./ A-27, Mohan Co-op. Indl. Estate
Mathura Road, New Delhi- 110 044
Ph. : +91 11 41578000 Ext.2564;DID.: +91 11 41578056 ;Mobile: +91 9871430022;
e mail: subhashmantri@panaceabiotec.com